Two-dimensional Gel Electrophoresis Map of Serum Proteins in Patients with Chronic Keshan Disease
Abstract
To identify the different serum proteins expressed in patients with Keshan disease (KD). Methods Two -dimensional gel electrophoresis (2-DE) was performed with serum samples from the patients with chronic KD and healthy controls to separate serum proteins. The gels were stained by sliver and scanned by Umax scanner. The data were analyzed by ImageMaster 2D software. KD related proteins were identified through searching the ExPASy-SWISS-2DPAGE database. Results Stable two-dimensional gel electrophoresis maps were established for serum samples of KD patients and healthy controls. A total of 808 and 814 protein spots were observed in KD patients and healthy controls, respectively. The two maps had 96.5475% identical protein spots and 44 differentially expressed protein spots. Eleven protein spots were expressed exclusively in KD patients and 12 protein spots only appeared in healthy controls. About 21 proteins were expressed in both groups but varied in quantities (14 proteins were over-expressed by more than 3 times and 7 proteins were under-expressed by more than 3 times in KD patients, P<0.01). Among the 353 protein spots matched with the ExPASy-SWISS-2DPAGE databank, No.1177 protein appeared in the KD patient was found to have the closest match with P02774 2-D0004T6 known as vitamin D binding protein (VDBP). Conclusion There is a significant difference in serum protein expression between KD patients and normal people. VDBP might play a role in cardiac muscle damage via inflammatory immune reactions.
Keywords: Keshan disease, Serum, Proteomics, Two-d imensional gel electrophoresis (2-DE)
Full Text:
PDFReferences
Gorg A, Postel W, Gunther S. The current state of two- dimensionalelectrophoresis with immobilized pH gradients. Electrophoresis, 2000; 21 (6): 1037-1053.
Yang SY. Xiao XY. Zhang WG. Et al. Application of serum SKI-DI proteomic patterns in diagnosis of lung cancer. BMC Cancer. 2005; 5:83.
Banfi C, Brioschi M. Wait R, et al. Proteomic analysis ofmembrane microdomains derived from both failing and non-failing human hearts. Proteomics,2006;6(6): 1976-1988.
Wilson PW. Cupples LA, Meigs JB. et al. Genome scan for impaired glycemic status: results from the Framingham Heart Study. Diabetes, 1997;46(Supple 1):76A.
Berger IXBeger HG. Evidence for endotoxin binding capacity of human Gc-globulin and transferr. Clin Chim Acta. 1987; 163 (3):289-299.
Kew RR. Mollison KW, Webster RO. Binding of Gc-globulin (vitamin D binding protein) to G5a or C5a des Arg is not necessary forf co-chemotacic activity. J Leukoc Biol. 1995; 58 (1); 55-58.
Yamamoto N. Kumahsiro R. Conversion of vitamin D3 binding protein (group-specific component) to a macro-phage activating factor by the stepwise action of beta-galactosidase of В cells and sialidase of T cells. J Immunol. 1993; 151 (5): 2794-2802.
Kamen DL.Tangpricha V. Vitamin D and moleculer actions on the immune system: modulation of innate and autoimmunity. J Mol Med (Berl) .2010;88(5):441-450.
Mocellin S. Targeting death receptors to fight cancer: from biological rational to clinical implementation. Curr Med ('hem. 2010;17(25):2713-2728.
Wiezorek J . Holland P. Graves J. Death receptor agonists as a targeted therapy for cancer. Clin Cancer Res, 2010; 16 ( 6): 1701-1708.
Trono D. Lentiviral vectors: turning a deadly foe into a therapeutic agent. Gene Ther,2000;7( 1);20-23.
Wiznerowicz M, Trono D. Harnessing HIV for therapy» basic research and biotechnology. Trends Biotechnol. 2005; 23 (1): 42-47.
Kim CY. Jeong M, Mushiake H. et al. Cancer gene therapy using a novel secretaire trimeric TRAIL. Gene Ther, 2006;
Xu К. Ma Н. McCown TJ. Et al. Generation of a stable cell line producing high-titer self-inactivating lentiviral vectors. Mol Ther.2001 ?3( 1 ):97-104.
Refbacks
- There are currently no refbacks.



